Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Investor webinar presentation 15 January 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to provide the attached presentation which will be delivered by the Company during an investor webinar at 1:00pm AEDT (10:00am AWST) on Thursday, 15 January 2026. The presentation provides shareholders with an update on the Company’s recent strategic and operational progress, including its strengthened funding position, regulatory developments, and preparation for commencement of patient enrolment in the HEALEY ALS Platform Trial. It also outlines Neurizon’s clinical strategy for lead asset NUZ-001, key near-term milestones, and the Company’s broader execution priorities for CY2026. Anyone wishing to attend the webinar must register via the link below: • Registration: https://bit.ly/15012026 • Date and time: 1:00pm AEDT (10:00am AWST) on Thursday, 15 January 2026 For investors who are unable to attend the webinar, a recording will be made available on the Company’s website at www.neurizon.com. -ENDS- This announcement has been authorised for release by Michael Thurn, Managing Director and CEO on behalf of the Board of Neurizon Therapeutics Limited. For further information, please contact: Neurizon Therapeutics Lidija Damjanovic Marketing & Corporate Affairs Email: lidija@neurizon.com Phone: +61 (0) 425 700 504 Australia Investor Relations Henry Jordan Six Degrees Investor Relations Email: henry.jordan@sdir.com.au Phone: +61 (0) 431 271 538 U.S. Investor Relations Matthew Selinger Integrous Communications Email: mselinger@integcom.us Phone: +1 415-572-8152 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited ABN 35 094 006 023 Neurizon Shareholder Webinar “Funding, Execution and Path Forward” Dr Michael Thurn, Managing Director & Chief Executive Officer January 2026 Disclaimer This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. Shareholder Webinar January 2026 2 Future Matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. US Disclosure This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers. To lead the development of neurodegenerative treatments towards a promising new horizon for patients. Our Vision Accelerating Patient Hope and Access to Innovative ALS Treatment Our Promise Driving Clinical Progress Unlocking the potential of Neurizon to address high unmet need in neurodegenerative diseases Delivering commercial readiness and stakeholder value Corporate Overview 5 Current Share Price (NUZ/NUZOA) $0.82/ $0.012 52 Week Low / High (NUZ) $0. 079/$0.175 No. of Shares (NUZ) 1 615,119,964 Listed Options (NUZOA) 116,705,765 Market Capitalisation $50.4m Cash (as at 30-Sep-25) $6.6m Debt (as at 30-Sep-25)2 ($1.5m) Net Cash $5.1m Enterprise Value $45.3m Unlisted Options (10c/15c/17.5c/20c/26c/33.25c) 26.501m Enterprise Value (fully diluted) $57.1m Capital Structure (AUD$) 9 January 2026 Share Price Performance Board & Management Top Shareholders (at 9 January 2026) Mid-stage biotechnology company targeting human neurodegenerative diseases Mr Sergio Duchini Chairman & Non-Executive Director Dr Michael Thurn Chief Executive Officer & Managing Director Mr Marcus Hughes Non-Executive Director Dr Katie MacFarlane Non-Executive Director Mr Dan O’Connell Chief Financial Officer Mr Stefan Ross Company Secretary Closing Price (AUD$) Volume (m) 1 Excludes 9,500,000 shares allocatedto Directors that are subject to approval, planned for the General Meeting in February 2026.. 2 Debt is a A$1.5m loan from Radium Capitalsecured against Australian R&D Rebate. SeeASX:NUZ “R&D Tax Incentive Advance & Overseas Finding Approval” 18 September 2025 - 1 2 3 4 5 6 0.00 0.10 0.20 0.30 0.40 0.50 9-Jan-25 9-Mar-25 9-May-25 9-Jul-25 9-Sep-25 9-Nov-25 9-Jan-26 Volume SP Mr Chek Loon Tan 6.34% Other Top 10 Shareholders 20.04% Board & Management1 3.60% Shareholder Webinar January 2026 Phase 1 Access to manufacturing at scale critical to future commercialisation Access to animal safety data and manufacturing data critical to support future trials and potential regulatory approvals Strongly Positioned with Regulatory and Commercialisation Requirements for Realisation Derisked regulatory approval process Drug / Dosage Form NUZ-001 Oral Tablets NUZ-001 Oral Tablets or Liquid Partnerships & Licensing HEALEY ALS Platform Trial Elanco Licensing Agreement Preclinical & research partners Amyotrophic Lateral Sclerosis (Motor Neurone Disease) Neurodegenerative DIseases • Identify Next Target Indication • Preclinical Data • First Patient In • 100% Enrolment Complete HEALEY ALS Platform Trial Indication Preclinical Phase 2 Phase 3 Approved/ Marketed Next Major Catalysts Accelerated approval possible on Phase 2 data and enabled through Elanco licensing Pivotal registration adaptive Phase 2/3 clinical study 6 Our Strategic Progress Focus remains on advancing ALS clinical program by commencing enrolment in the HEALEY ALS Platform Trial (Phase 2/3) Shareholder Webinar January 2026 Demonstrating Meaningful Progress: FY 2026 Milestones Successfully raised $7.1m through a share placement 7 Executed Global License Agreement with Elanco NUZ-001 IND Opened, clearing the path to HEALEY First registration batch of NUZ-001 Preliminary R&D Funding received Top-line results from OLE study JP Morgan Health Conference Partnering and Participation R&D Tax Incentive Advance & Overseas Finding Approval Established a $20m strategic con note facility with Obsidian Australian Patent granted for NUZ-001 – Expiry 2041 Shareholder Webinar January 2026 Entering The Next Phase Of Value Creation: HEALEY ALS Platform Trial HEALEY ALS Platform Trial NUZ-001 cleared for entry into the HEALEY ALS Platform Trial HEALEY ALS Platform Trial is a competitive process led by a group of expert ALS scientists and members of the Healey Science Advisory Committee 9 HEALEY ALS Platform Trial Design Patient Enrolls in Platform Trial Active Active Active Placebo Placebo Placebo Placebo Active Active Active Placebo Active Active Active Placebo Regimen H Regimen I Regimen J Shared Placebo Shared infrastructure and common protocol, allowing sharing of placebo participants Randomization Randomization Randomization Randomization FDA approved Master Protocol Design • Shared master protocol • >70 clinical sites across the US • 3:1 active drug to placebo ratio • 160 participants per regimen • 7 regimens completed • 2 regimens progressing to Phase 3 Innovative Trial Structure NUZ-001 30% reduction in research cost The platform trial tests multiple treatments at once reducing cost of research 50% faster Trial times are expected to be cut in half due to the established infrastructure and rapid recruitment 67% more participants The platform’s broad reach recruits more people and brings them faster access to innovative therapies Completed Regimens Advantages of Platform Trials over Standard Trials Shareholder Webinar January 2026 HEALEY ALS Platform Trial Regimen ‘I’ for NUZ-001 10 Screening Period 36-week Double blind Placebo Controlled Period 36-week Active Treatment Extension Period 3:1 Randomization n=160 patients Primary Endpoint • Change from baseline through Week 36 in disease severity, measured by the ALSFRS-R total score and survival Secondary Endpoints • Change from baseline through Week 36 in secondary efficacy measures (e.g., respiratory function via slow vital capacity (SVC)) • Survival through Week 36 (death or equivalent endpoint) ALSFRS-R Biomarkers DNA NUZ-001 10 mg/kg Placebo NUZ-001 10 mg/kg Shareholder Webinar January 2026 Enrollment Complete Q3-Q4 2026 Q1 2026 4 5 First Patient Randomised 160 patients enrolled in the trial First patient screened for eligibility Last Patient Dosed 3 Q1 2026 First Patient Screened 6 NUZ-001 entry accepted Q2-Q3 2027 Last participant receives final dose Q4 2025 Database Lock Q3 2027 FDA Clearance 7 Platform Trial IND submitted to regulatory authorities Clinical trial database locked for analysis Q4 2025 Topline Data Released IND Amendment Submission Topline results of the trial announced 8 Q3 2027 First participant randomized into treatment regimen 11 ‘Regimen-I’ HEALEY ALS Platform Trial Expected Key Milestones FDA cleared NUZ-001 for entry into HEALEY ALS Platform Trial. The first patient in the trial is expected to be enrolled in Q1 2026. Shareholder Webinar January 2026 Regulatory and Market Update Fast Track Designation – Regulatory Context and Program Continuity Fast Track Designation Status Neurizon received correspondence from the U.S. FDA advising that Fast Track Designation for NUZ-001 in ALS was not granted at this time. The FDA confirmed that ALS is a serious condition with an unmet medical need. The FDA provided constructive feedback outlining the additional clinical data that could support a future Fast Track request as NUZ-001 advances through development. Shareholder Webinar January 2026 13 What This Means for NUZ ALS Program Fast Track Designation is a procedural mechanism and is not required to progress clinical development or pursue regulatory approval. The FDA indicated that additional clinical data are required at this stage to demonstrate differentiation from approved therapies. This feedback provides clarity on data expectations and helps inform future regulatory planning. Development and Execution Remain on Track NUZ-001 has advanced into the next operational phases of the HEALEY ALS Platform Trial. IRB submissions, clinical site activation and study start-up activities are underway. Secured sufficient funding to complete this registration-adaptive Phase 2/3 trial. As additional clinical data becomes available, we will evaluate the optimal timing for a Fast Track resubmission. Regulatory guidance received with clinical execution proceeding as planned Key Context for Fast Track Designation • Timing varies across ALS programs and is dependent on data maturity at the time of application • Designation is not predictive of regulatory approval or clinical success • Regulatory outcomes are determined by the quality, maturity, and completeness of clinical data, which the HEALEY ALS Platform Trial is designed to generate Accelerated & Streamlined Path to NDA and Launch Elanco License Agreement 14 • Comprehensive non- clinical safety package • Complete API GMP documentation of the manufacturing process for the FDA • Improves alignment with FDA module expectations • De-risked regulatory approval process Sample Text Sample Text Clinical 5 MODULE 5 MODULE 4 MODULE 3 MODULE 2 MODULE 1 4 3 Non-clinical Quality Summary Documents 2 Admin 1 Elanco License Agreement • Strengthens NDA readiness • Reduces development cost • Supports accelerated timeline & launch readiness Future Fast Track Designation allows for rolling submission of completed modules API = Active Pharmaceutical Ingredient; GMP = Good Manufacturing Practices; NDA = New Drug Application Shareholder Webinar January 2026 Major Pharma Investment Validates ALS Commercial Opportunity Shareholder Webinar January 2026 15 Shionogi transaction represents a meaningful external validation of the ALS market and improves the strategic, commercial, and partnering backdrop for Neurizon’s NUZ-001 program • USD $2.5B deal validates ALS market • ALS now a strategic pharma priority • Unmet need persists beyond Edaravone • Partnering and M&A optionality expands • Established regulatory and reimbursement precedent lowers barriers for NUZ-001 Edaravone FDA approved in 2017 List price US$171,000 ~US$1 billion in sales1 1. . Research Reports World 2024. Strategic Funding Placement & Entitlement Offer2 • Firm commitments to raise ~A$7.1 million under the Placement, through issue of New Shares at A$0.08 per New Share for the HEALEY ALS Platform Trial • 2-for-5 Entitlement Offer to raise up to ~A$17.1 million at A$0.08 per New Share, with funds allocated to other working capital. Research & Development (R&D) Tax Rebate • Neurizon’s Advance and Overseas Finding (AOF) provides a cash rebate for foreign R&D spend • Cash rebate of at least 43.5% on HEALEY spend • AOF is binding on Australian Tax Office and AusIndustry - providing an important, non- dilutive source of funds Convertible Note Facility3 • Convertible Note Facility for up to A$20 million with Obsidian Global GP, LLC • Initial draw of only A$5 million • Committed facility - option but no obligation to use • Includes trading restrictions to protect shareholder and optionholder interests Neurizon’s strategy is to efficiently secure adequate funding for the HEALEY ALS Platform Trial, to enable the Company to commit to it1. The strategy is focused on protecting shareholders’ interests through flexible funding and minimising dilution. 17 HEALEY Funding Strategy Focused on flexibly and efficiently securing adequate funding for the HEALEY ALS Platform Trial 1 Existing cash holdings, the Placement, the Research and Development Tax Rebate and the committed funds through the Convertible Note Facility, will provide adequate secured funding for Neurizon to commit to and commence the HEALEY ALS Platform Trial. The Convertible Note Facility is subject to a number of conditions, including shareholder approval. 2 The issue of Shares to Directors under the Placement is subject to shareholder approval. The Company is also undertaking a 2 for 5 pro-rata Entitlement Offer to eligible shareholders to raise up to ~A$17.1 million, at the same Offer Price as the Placement. Any funds raised from the Entitlement Offer will be used to for working capital purposes. Shareholder Webinar January 2026 Offer Overview 18 Offer Structure Up to ~A$24.2 million via the issue of up to ~303.5 million new fully paid ordinary shares in the Company (“New Shares”) comprising: • an ~A$7.1 million placement via the issue of ~89.2 million New Shares to certain eligible institutional, sophisticated or professional investors (“Placement”). Includes ~9.8 million New Shares to raise ~A$0.8 million to Directors and Management subject to shareholder approval; • up to ~A$17.1 million (up to ~214.3 million New Shares) 2 for 5 non-renounceable entitlement offer (“Entitlement Offer”, together with the Placement, the “Offer”). Offer Price “Offer Price” of A$0.08 per New Share represents: • 27.3% discount to the last closing price of A$0.11 on 18 December 20251; • 27.3% discount to the 5-day volume weighted average trading price of A$0.11 to 18 December 2025.1 Use of funds • Funds raised from the Placement will be used to partially fund commencement of the HEALEY ALS Platform Trial. • Any funds raised from the Entitlement Offer will be used for working capital purposes. • See slide 32 for further details. Ranking Shares will rank equally with existing fully paid ordinary shares of the Company (“Shares”) on issue from date of issue. Lead Manager Morgans Corporate Limited (“Lead Manager”) has been appointed as placement agent (in respect of the Placement) and lead manager and bookrunner (in respect of the Entitlement Offer). Underwriting Neither the Placement nor the Entitlement Offer is underwritten. 1 Source IRESS. Shareholder Webinar January 2026 Timetable1 19 Trading Halt Friday, 19 December 2025 Trading Halt Lifted and Return to Trading on the ASX, Announce Results of Placement, Announce Entitlement Offer Tuesday, 23 December 2025 Entitlement Offer ‘Ex’ Date Monday, 29 December 2025 Entitlement Offer Record Date Tuesday, 30 December 2025 Placement Settlement Date Wednesday, 31 December 2025 Placement Allotment Date Friday, 2 January 2026 Entitlement Offer Documents Dispatched to Eligible Shareholders, Entitlement Offer Opening Date Monday, 5 January 2026 Last Day to Extend the Entitlement Offer Closing Date Before noon, Friday, 16 January 2026 Entitlement Offer Closing Date 5.00pm, Wednesday, 21 January 2026 Securities Quoted on a Deferred Settlement Basis from Market Open Thursday, 22 January 2026 Announce Results of Entitlement Offer Tuesday, 27 January 2026 Entitlement Offer Settlement Date Wednesday, 28 January 2026 Entitlement Offer Allotment Date Thursday, 29 January 2026 Commencement of Trading of New Shares Issued under the Entitlement Offer on ASX Friday, 30 January 2026 Dispatch of Holding Statements for New Shares issued under the Entitlement Offer Friday, 30 January 2026 General Meeting to approve Director and Management Placement Participation and Convertible Note Facility February 2026 1 Timetable is indicative only and may be subject to change at the sole discretion of the Company, in consultation with the Lead Manager, in compliance with the ASX Listing Rules and Corporations Act 2001 (Cth). Shareholder Webinar January 2026 Upcoming Milestones Near-Term Milestones Objectives 21 Q1 Q2 CY 2026 ONGOING EFFORTS • Preclinical Updates • HEALEY Updates • Liquid Formulation PK Study Initiation • PDMA Regulatory Consultation • American Academy of Neurology Meeting, Target ALS, and other major international conferences and partnering events ✓HEALEY ALS Platform Trial– IRB Approval ✓44th J.P. Morgan Annual Healthcare Conference and other events • Australian R&D Refund (net of R&D funding) • Preclinical Updates • HEALEY Investigator Meeting • HEALEY ALS Platform Trial – First Patient Dosed • Commercial Supply Agreement with Elanco • Fierce Biotech Webinar with HEALEY • EMA Scientific Advice meeting • Ethics Approval for Liquid Formulation PK Study ✓ Work to broaden pipeline to other neurodegenerative diseases ✓ Partnership expansion opportunities with patient associations ✓ Targeted engagement with potential strategic partners Shareholder Webinar January 2026 Shareholder Webinar January 2026 22 Registration now open! https://www.fiercebiotech.com/premium/we binar/1375715 23 Well-characterised Drug • First-in-class small molecule • Validated blood brain barrier penetration • Established long term safety profile. Disease-modifying potential • Phase 1 (n=12) suggests 16-month survival extension; (SOC 3 month) • Targets underlying pathology – protein aggregation • Favorable biomarker response profile Phase 2/3 Ready • FDA Cleared entry into HEALEY ALS Platform Trial • First Patient in Q1 2026 • Long-term safety profile and efficacy signals in Phase 1 and OLE studies Current ALS Treatments • High unmet need for disease modifying treatment • Limited efficacy with current options NUZ-001 Opportunity • 15% annual sales growth rate of ALS market, $1.28B by 2029 • 0.8% annual ALS patient population growth • Potential for platform molecule Strong Market Readiness • Patent protection in US and AU out to 2041, with EU and JP pending • EMA Orphan Medicinal Product Designation • FDA Orphan Drug Designation ✓ ✓ ✓ ✓ ✓ ✓ NUZ-001: Orphan Drug Designated Small Molecule Showing Promising Survival Trends in ALS Shareholder Webinar January 2026 Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com THANK YOU Appendix 1 - International Offer Restrictions International Offer Restrictions This presentation does not constitute an offer of New Shares of the Company in any jurisdiction in which it would be unlawful. In particular, this presentation may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below. Hong Kong WARNING: This presentation has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the “SFO”). Accordingly, this presentation may not be distributed, and the New Shares may not be offered or sold, in Hong Kong other than to “professional investors” (as defined in the SFO and any rules made under that ordinance). No advertisement, invitation or presentation relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities. The contents of this presentation have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this presentation, you should obtain independent professional advice. New Zealand This presentation has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the “FMC Act”). The New Shares are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who: • is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act; • meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act; • is large within the meaning of clause 39 of Schedule 1 of the FMC Act; • is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or • is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act. Singapore This presentation and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this presentation and any other presentation or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the “SFA”) or another exemption under the SFA. This presentation has been given to you on the basis that you are an “institutional investor” or an “accredited investor” (as such terms are defined in the SFA). If you are not such an investor, please return this presentation immediately. You may not forward or circulate this presentation to any other person in Singapore. Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singapore may be applicable to investors who acquire New Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly. 26 Shareholder Webinar January 2026 International Offer Restrictions United Kingdom Neither this presentation nor any other presentation relating to the offer has been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (“FSMA”)) has been published or is intended to be published in respect of the New Shares. The New Shares may not be offered or sold in the United Kingdom by means of this presentation or any other presentation, except in circumstances that do not require the publication of a prospectus under section 86(1) of the FSMA. This presentation is issued on a confidential basis in the United Kingdom to “qualified investors” within the meaning of Article 2(e) of the UK Prospectus Regulation. This presentation may not be distributed or reproduced, in whole or in part, nor may its contents be disclosed by recipients, to any other person in the United Kingdom. Any invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) received in connection with the issue or sale of the New Shares has only been communicated or caused to be communicated and will only b